Clinical Interest in Exome-Based Analysis of Somatic Mutational Signatures for Non-Small Cell Lung Cancer.

Date publication

septembre 2024

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François , Mme TRUNTZER Caroline , Dr DERANGERE Valentin

Tous les auteurs :
Peroz M, Mananet H, Roussot N, Kaderbhai CG, Derangère V, Truntzer C, Ghiringhelli F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39272973

Résumé

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality. This study investigates the clinical interest of whole exome sequencing (WES) for analyzing somatic mutational signatures in patients with advanced or metastatic NSCLC treated with the current standard of care.

Mots clés

immune checkpoint inhibitors, non-small cell lung cancer, prognostic biomarkers, somatic mutational signatures, whole exome sequencing

Référence

Cancers (Basel). 2024 09 9;16(17):